97 related articles for article (PubMed ID: 12102551)
1. Molecular characterization of p53 mutations in primary and secondary liver tumors: diagnostic and therapeutic perspectives.
Tullo A; Sbisà E
Mol Biotechnol; 2002 Jul; 21(3):265-78. PubMed ID: 12102551
[TBL] [Abstract][Full Text] [Related]
2. The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas.
Sugo H; Takamori S; Kojima K; Beppu T; Futagawa S
Surg Today; 1999; 29(9):849-55. PubMed ID: 10489124
[TBL] [Abstract][Full Text] [Related]
3. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.
Tolbert DM; Noffsinger AE; Miller MA; DeVoe GW; Stemmermann GN; Macdonald JS; Fenoglio-Preiser CM
Mod Pathol; 1999 Jan; 12(1):54-60. PubMed ID: 9950163
[TBL] [Abstract][Full Text] [Related]
4. P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection.
Yang Y; Forslund A; Remotti H; Lönnroth C; Andersson M; Brevinge H; Svanberg E; Lindnér P; Hafström L; Naredi P; Lundholm K
Cancer; 2001 Feb; 91(4):727-36. PubMed ID: 11241240
[TBL] [Abstract][Full Text] [Related]
5. [Mutation analysis of the tumor suppressor gene PTEN/MMAC1/TEP1 in human hepatocellular carcinoma].
Zhang LN; Zha XL; Yu Q; He JY
Shi Yan Sheng Wu Xue Bao; 2000 Sep; 33(3):223-7. PubMed ID: 12549040
[TBL] [Abstract][Full Text] [Related]
6. p53 abnormalities in hepatocellular carcinoma from United States patients: analysis of all 11 exons.
Kazachkov Y; Khaoustov V; Yoffe B; Solomon H; Klintmalm GB; Tabor E
Carcinogenesis; 1996 Oct; 17(10):2207-12. PubMed ID: 8895490
[TBL] [Abstract][Full Text] [Related]
7. High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma.
Anzola M; Saiz A; Cuevas N; Lopez-Martinez M; Martinez de Pancorbo MA; Burgos JJ
J Viral Hepat; 2004 Nov; 11(6):502-10. PubMed ID: 15500550
[TBL] [Abstract][Full Text] [Related]
8. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.
Honda K; Sbisà E; Tullo A; Papeo PA; Saccone C; Poole S; Pignatelli M; Mitry RR; Ding S; Isla A; Davies A; Habib NA
Br J Cancer; 1998 Mar; 77(5):776-82. PubMed ID: 9514057
[TBL] [Abstract][Full Text] [Related]
9. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
11. Characterization of p53 mutations in colorectal liver metastases and correlation with clinical parameters.
Tullo A; D'Erchia AM; Honda K; Mitry RR; Kelly MD; Habib NA; Saccone C; Sbisà E
Clin Cancer Res; 1999 Nov; 5(11):3523-8. PubMed ID: 10589767
[TBL] [Abstract][Full Text] [Related]
12. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan.
Hayashi H; Sugio K; Matsumata T; Adachi E; Takenaka K; Sugimachi K
Hepatology; 1995 Dec; 22(6):1702-7. PubMed ID: 7489977
[TBL] [Abstract][Full Text] [Related]
13. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
14. p53 Mutations are present in colorectal cancer with cytoplasmic p53 accumulation.
Jansson A; Gentile M; Sun XF
Int J Cancer; 2001 May; 92(3):338-41. PubMed ID: 11291068
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
[TBL] [Abstract][Full Text] [Related]
17. Detection of p53 Mutations in Circulating DNA of Transplanted Hepatocellular Carcinoma Patients as a Biomarker of Tumor Recurrence.
García-Fernández N; Macher HC; Rubio A; Jiménez-Arriscado P; Bernal-Bellido C; Bellido-Díaz ML; Suárez-Artacho G; Guerrero JM; Gómez-Bravo MA; Molinero P
Adv Exp Med Biol; 2016; 924():25-28. PubMed ID: 27753013
[TBL] [Abstract][Full Text] [Related]
18. Murine p53 intron sequences 5-8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CD-1 mouse liver and lung tumors.
Goodrow TL; Storer RD; Leander KR; Prahalada SR; van Zwieten MJ; Bradley MO
Mol Carcinog; 1992; 5(1):9-15. PubMed ID: 1543544
[TBL] [Abstract][Full Text] [Related]
19. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.
Jablkowski M; Bocian A; Bialkowska J; Bartkowiak J
J Exp Clin Cancer Res; 2005 Mar; 24(1):117-25. PubMed ID: 15943041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
